As of 2023, more than 100 Ab drugs have been approved by FDA, most of them were generated by hybridoma and phage library. However, as a newly emerged technology, single B cell approach contributed 20% of approved drug during the last four years. Comparing to traditional technology, single B cell screening featured with shorter timeline, better diversity and better developability due to cognate pairing of Ab heavy & light chain, but limited screening sensitivity and assay flexibility has been the major bottleneck preventing its further expansion to wider application scenario. To tackle with these issues, here ProBio will introduce a newly upgraded single B cell platform, featured with capability of screening for both IgG and VHH antibody, and HTP cell-to-antibody conversion system without sequencing or gene synthesis.